Superworth

Avalo Therapeutics EPS AVTX

Diluted earnings per share by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
−$4.75
Latest quarter, Q2 FY26
−$0.83
Fiscal year 2025
−$6.11

Avalo Therapeutics' earnings per share was −$4.75 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.83.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$6.11n/a
FY2024−$161.49n/a
FY2023−$381.75n/a
FY2022−$1063.60n/a
FY2018−$3456.00−1600%
FY2017$230.40n/a
FY2016−$5414.40n/a
FY2015−$31824.00n/a
FY2014−$16214.40n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.83n/a−$4.75
Q1 FY26−$0.98n/a−$5.84
Q4 FY25−$0.75n/a−$6.11
Q3 FY25−$2.19n/a−$8.81
Q2 FY25−$1.92n/a−$9.45
Q1 FY25−$1.25n/a−$21.60
Q4 FY24−$3.45n/a−$161.49
Q3 FY24−$2.83n/a−$168.23
Q2 FY24−$14.07n/a−$192.23
Q1 FY24−$141.14n/a−$318.89
Q4 FY23−$10.19n/a−$381.75
Q3 FY23−$26.83−133%−$621.56

Against its peers

Companies in Drug Manufacturers - General nearest Avalo Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
AVTXAvalo Therapeutics−$4.75
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
NATRNatures Sunshine Products$1.01+36% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
AMPHAmphastar Pharmaceuticals$1.70−36% a year
OMEROmeros$1.52
Peer median$0.97

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Avalo Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.